Demand for a COVID-19 treatment has soared alongside a surge in Delta variant infections. Monoclonal antibodies (mAbs) are being promoted by politicians, doctors, and local
Last Tuesday, in a White House briefing, Dr. Anthony Fauci highlighted what he called an “underutilized” treatment in the battle against COVID-19. Monoclonal antibodies (mAbs)
COVID-19 varients and breakthrough cases are placing therapeutics back in the national spotlight. Monoclonal antibody therapies (mAbs) have received particular attention as they increasingly receive
Read Article
Read this article
Read this article
Read this article
Please note that mAbs At Home provides monoclonal antibody treatments utilizing several types of FDA authorized monoclonals. Circulating SARS-CoV-2 viral variants, including Omicron, may be associated with resistance to monoclonal antibodies. The frequency of the Omicron variant is increasing throughout the U.S. Data shows that it is unlikely that Eli Lilly’s bamlanivimab and etesevimab or Regenron’s REGEN-COV will retain activity against this variant. GSK’s Sotrovimab appears to retain activity against the Omicron variant. Mabs At Home is currently following guidance by reserving GSK’s Sotrovimab for only the highest-risk patients.
